• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Cosmos Health Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    10/1/25 6:02:51 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care
    Get the next $COSM alert in real time by email
    cosm_8k.htm
    0001474167false--12-3100014741672025-09-302025-09-30iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported) September 30, 2025

     

    Cosmos Health Inc.

    (Exact name of registrant as specified in its charter)

     

    Nevada

     

    000-54436

     

    27-0611758

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification No.)

     

    5 AGIOU GEORGIOU, Pilea, Thessaloniki, Greece

     

    55438

    (Address of principal executive offices) 

     

    (Zip Code)

     

    Registrant’s telephone number, including area code (312) 865-0026

     

    (Former name or former address, if changed since last report.)

     

    Title of Each Class

     

    Trading

    Symbol

     

    Name of Each Exchange

    On Which Registered

    Common Stock, $.001 par value

     

    COSM

     

    Nasdaq Capital Market

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13a-4(c))

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

    ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.

     

    As described under Item 5.07 of this Current Report on Form 8-K, at the Company’s 2025 Annual Meeting of Stockholders held on September 30, 2025 (the “Annual Meeting”), the stockholders of the Company elected the following to serve as directors of the Company until the next Annual Meeting and until their successors are duly elected and qualified:  

     

    Grigorios Siokas

    Demetrios G. Demetriades

    John J. Hoidas

    Dr. Anastasios Aslidis

    Suhel Bhutawala

    Theodoros C. Karkantzos

     

    ITEM 5.03. AMENDMENTS TO ARTICLES OF INCORPORATION OR BYLAWS; CHANGE IN FISCAL YEAR.

     

    As described under Item 5.07 of this Current Report on Form 8-K, at the Company’s 2025 Annual Meeting of Stockholders held on September 30, 2025 (the “Annual Meeting”), the stockholders of the Company approved the proposed amendment (the “Amendment”) to the Company’s Articles of Incorporation to increase the number of authorized shares of capital stock of the Company to 1,500,000,000 shares of Common Stock and 300,000,000 shares of “blank check” Preferred Stock. The Amendment is described in detail under “Proposal Eight: Approval Of The Amendment To The Company’s Articles Of Incorporation To Increase The Number Of Authorized Shares Of Capital Stock Of The Company To 1,500,000,000 Shares Of Common Stock And 300,000,000 Shares Of “Blank Check” Preferred Stock,” commencing on page 45 of the Company’s definitive proxy statement filed with the Securities and Exchange Commission on August 22, 2025 in connection with the Annual Meeting. The Amendment will become effective upon its filing with the Secretary of State of the State of Nevada. The description of the Amendment is qualified in its entirety by reference to the full text of the Amendment to the Articles of Incorporation, which is filed with this Current Report on Form 8-K as Exhibit 3.1 and is incorporated herein by reference.

     

    ITEM 5.07. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.

     

    On September 30, 2025, the Company held the Annual Meeting. Of the 30,127,379 shares of common stock of the Company outstanding on the record date, 15,983,371 shares were present at the Annual Meeting in person or by proxy, representing approximately 53% of the total outstanding shares eligible to vote. All proposals passed, and the directors recommended by the Company were elected.

     

    The final results for each of the matters submitted to a vote of stockholders at the Annual Meeting are as follows:

     

    Proposal 1 – Election of Directors

     

    Name

     

    Votes For

     

     

    Votes Withheld

     

    Grigorios Siokas

     

     

    13,799,035

     

     

     

    2,184,336

     

    Demetrios G. Demetriades

     

     

    12,216,173

     

     

     

    3,767,198

     

    John J. Hoidas

     

     

    12,220,515

     

     

     

    3,762,856

     

    Dr. Anastasios Aslidis

     

     

    12,038,933

     

     

     

    3,944,438

     

    Suhel Bhutawala

     

     

    12,037,608

     

     

     

    3,945,763

     

    Theodoros C. Karkantzos

     

     

    12,035,428

     

     

     

    3,947,943

     

     

     
    2

     

     

    Proposal 2 – Authorization of the Board of Directors to Amend the Company’s Amended and Restated Articles of Incorporation to Effect a Reverse Stock Split of the Company’s Outstanding Common Stock at their Discretion

      

    Votes For:

     

     

    13,898,821

     

    Votes Against:

     

     

    2,084,235

     

    Abstain:

     

     

    315

     

     

    Proposal 3 – Approval of the Issuance of Shares of Common Stock Issuable Upon Conversion of the Notes in Compliance with Nasdaq Listing Rule 5635(d)

      

    Votes For:

     

     

    13,961,150

     

    Votes Against:

     

     

    2,022,033

     

    Abstain:

     

     

    188

     

     

    Proposal 4 – The Ratification of the Appointment of the Company’s Independent Registered Public Accounting Firm

     

    Votes For:

     

     

    14,040,370

     

    Votes Against:

     

     

    1,939,314

     

    Abstain:

     

     

    3,687

     

     

     

    Proposal 5 – Approval of Company’s 2025 Equity Omnibus Plan

     

    Votes For:

     

     

    13,982,769

     

    Votes Against:

     

     

    1,951,983

     

    Abstain:

     

     

    48,619

     

     

    Proposal 6 – Non-Binding Advisory on “Say on Pay” Vote

     

    Votes For:

     

     

    13,867,716

     

    Votes Against:

     

     

    1,968,122

     

    Abstain:

     

     

    147,533

     

     

    Proposal 7 – Non-Binding Advisory on the Frequency of the Future “Say on Pay” Votes

     

    One Year:

     

     

    2,658,606

     

    Two Years:

     

     

    51,510

     

    Three Years:

     

     

    13,082,602

     

    Abstain:

     

     

    190,653

     

     

    Proposal 8 – Approval Of The Amendment To The Company’s Articles Of Incorporation To Increase The Number Of Authorized Shares Of Capital Stock Of The Company To 1,500,000,000 Shares Of Common Stock And 300,000,000 Shares Of “Blank Check” Preferred Stock

     

    Votes For:

     

     

    13,802,295

     

    Votes Against:

     

     

    2,176,907

     

    Abstain:

     

     

    4,169

     

     

     
    3

     

     

    ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

     

    (d) Exhibits:

     

    Exhibit No.

    Description

    3.1

    Certificate of Amendment to the Articles of Incorporation of Cosmos Health, Inc., dated as of September 30, 2025.

     104

     

     Cover Page Interactive Date File (embedded within the Inline XBRL document)

     

     

    4

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    COSMOS HEALTH INC.

     

     

     

     

    Date: September 30, 2025

    By:

    /s/ Georgios Terzis

    Georgios Terzis

     

    Chief Financial Officer

     

     

     
    5

     

    Get the next $COSM alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $COSM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $COSM
    SEC Filings

    View All

    Cosmos Health Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - Cosmos Health Inc. (0001474167) (Filer)

    10/1/25 6:02:51 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    SEC Form DEFA14A filed by Cosmos Health Inc.

    DEFA14A - Cosmos Health Inc. (0001474167) (Filer)

    9/29/25 5:04:10 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Cosmos Health Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Cosmos Health Inc. (0001474167) (Filer)

    9/29/25 9:59:07 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $COSM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cosmos Health CEO Issues Letter to Shareholders: Building a Global Healthcare Powerhouse with $300M Digital Financing Facility, U.S. Manufacturing Expansion, and AI Innovation

    CHICAGO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ: COSM), a diversified, vertically integrated global healthcare group, today announced that its Chief Executive Officer, Greg Siokas, has issued the following letter to the Company's shareholders. Dear Fellow Shareholders, Cosmos Health stands at a defining moment in its journey. Over the past year, we have made decisive progress - refining our strategy, reinforcing our operations, and positioning every business unit to contribute to a common vision of sustainable growth and long-term value creation. From our expanding manufacturing footprint in the United States to the global reach

    9/29/25 8:00:07 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Cosmos Health Expands Order Book with Contract Manufacturing Agreement with Medical Pharmaquality S.A. for 3 Million MYCOFAGYL® Pessaries Annually

    CHICAGO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ: COSM), a diversified, vertically integrated global healthcare group, today announced that its wholly owned subsidiary, Cana Laboratories S.A. ("Cana"), has signed a contract manufacturing agreement with Medical Pharmaquality S.A. for MYCOFAGYL® pessaries, further expanding its pipeline of pharmaceutical products. Under the terms of the agreement, Cana will manufacture MYCOFAGYL®, a combination of Metronidazole (500mg) and Nystatin (100,000 IU) in pessary dosage form. The product will be supplied in packs of 10 units (2 PVC/PE strips x 5 pessaries). The Company anticipates manufacturi

    9/25/25 8:00:00 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Cosmos Health Expands Presence in the $7 Billion GCC Nutraceuticals Market, Signs Distribution Agreement with Scientific Pharmacy for Sky Premium Life in Oman, Including Initial Purchase Order of 42,000 Units

    CHICAGO, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that its wholly owned subsidiary, Sky Pharm SA, signed a distribution agreement (the "Agreement") with Scientific Pharmacy LLC ("Scientific Pharmacy") for its Sky Premium Life food supplement products in Oman. Scientific Pharmacy, the retail and wholesale arm of Planet Pharmacies in Oman, is a leading healthcare and beauty company offering integrated distribution and retail services. Known for its international brand partnerships and strong customer focus, it has become a trusted name in Oman and cont

    9/11/25 8:00:37 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $COSM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Siokas Grigorios bought $15,217 worth of shares (34,004 units at $0.45), increasing direct ownership by 0.56% to 6,158,884 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    5/27/25 9:33:43 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Chief Executive Officer Siokas Grigorios bought $62,800 worth of shares (141,825 units at $0.44), increasing direct ownership by 2% to 6,124,880 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    5/23/25 12:18:06 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Chief Executive Officer Siokas Grigorios bought $82,000 worth of shares (174,172 units at $0.47), increasing direct ownership by 3% to 5,983,055 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    5/22/25 10:33:17 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $COSM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Siokas Grigorios bought $15,217 worth of shares (34,004 units at $0.45), increasing direct ownership by 0.56% to 6,158,884 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    5/27/25 9:33:43 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Chief Executive Officer Siokas Grigorios bought $62,800 worth of shares (141,825 units at $0.44), increasing direct ownership by 2% to 6,124,880 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    5/23/25 12:18:06 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Chief Executive Officer Siokas Grigorios bought $82,000 worth of shares (174,172 units at $0.47), increasing direct ownership by 3% to 5,983,055 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    5/22/25 10:33:17 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $COSM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Cosmos Health Inc.

    SC 13G/A - Cosmos Health Inc. (0001474167) (Subject)

    11/14/24 4:50:24 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    SEC Form SC 13G filed by Cosmos Health Inc.

    SC 13G - Cosmos Health Inc. (0001474167) (Subject)

    2/14/24 3:33:29 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    SEC Form SC 13D/A filed by Cosmos Health Inc. (Amendment)

    SC 13D/A - Cosmos Health Inc. (0001474167) (Subject)

    7/25/23 4:06:11 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $COSM
    Leadership Updates

    Live Leadership Updates

    View All

    Cosmos Health Reports Full-Year 2024 Results: Revenue Increases 2% to $54.43 Million While Operating Expenses Decline 24.2% to $19.86 Million

    CHICAGO, April 16, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, today reported financial results for the full year ended December 31, 2024. Full Year 2024 Financial Highlights Income Statement: FY 2024 performance was marked by revenue growth, an increase in R&D investments, and a substantial reduction in operating expenses, while bottom-line results were impacted by the absence of non-recurring gain

    4/16/25 12:45:15 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Cosmos Health Strengthens R&D Leadership and Innovation with the Appointment of Professor Dimitrios Trafalis, MD, as Head of Oncology

    CHICAGO, IL / ACCESSWIRE / December 26, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today the appointment of Professor Dimitrios Trafalis, MD, as Head of Oncology at the Company's Research and Development division.Professor Trafalis currently serves as a Professor of Pharmacology and Clinical Pharmacology at the Faculty of Medicine, National and Kapodistrian University of Athens.He is a medical specialist in onc

    12/26/24 1:30:00 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Cosmos Health Reports Q3 2023 Results; Revenue Increased 7% YoY, Total Assets Reached Record $71.5M with Stockholders' Equity of $44.2M or $3.4/Share

    THESSALONIKI, GREECE / ACCESSWIRE / November 21, 2023 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, today provided a business update and reported financial results for the third quarter and nine months ended September 30, 2023.Third Quarter 2023 Financial HighlightsRevenues increased to $12.8 million from $12.0 million in Q3 2022, largely due to increased sales attributable to the logistics distribution business, which expanded

    11/21/23 9:00:00 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $COSM
    Financials

    Live finance-specific insights

    View All

    Cosmos Health CEO Greg Siokas Acquires 1,466,764 Shares Valued at $526,000 Over the Past Week; 2,777,469 Shares Acquired Over the Past Five Months for $1,325,000

    CHICAGO, April 30, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its CEO, Greg Siokas, has increased his stake in the Company by acquiring a total of 1,466,764 common shares, valued at $526,000, across five transactions between April 21, 2025, and April 24, 2025. As a result of these transactions, Mr. Siokas now beneficially owns 5,582,066 common shares in Cosmos Health. Greg S

    4/30/25 12:50:09 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Cosmos Health CEO Greg Siokas Acquires a Total of 647,809 Shares Valued at $425,000 Over the Past 32 Days

    CHICAGO, IL / ACCESS Newswire / January 21, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its CEO, Greg Siokas, has increased his stake in the Company by acquiring a total of 647,809 common shares, valued at $425,000, across six transactions between December 20, 2024, and January 17, 2025.As a result of these transactions, Mr. Siokas now beneficially owns 4,164,789 common shares in Cosmos Health.Greg Si

    1/21/25 3:00:00 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Cosmos Health Issues Letter to Shareholders

    CHICAGO, IL / ACCESSWIRE / November 12, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its Chief Executive Officer, Greg Siokas, has issued the following letter to the Company's shareholders.Dear Cosmos Health Shareholders,It has been just over a year since my previous shareholder letter, and I would like to express my sincere gratitude for your continued support. We have achieved many positive milestone

    11/12/24 12:01:41 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care